Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Porustobart + Toripalimab in Advanced Solid Tumors
NCT04727164Phase 1Unknown
- Sponsor
- Harbour BioMed
- Start
- Feb 2021
- Primary completion
- Nov 2023
- Modality
- Antibody Conjugates, Nanobodies (VHH), Monoclonal Antibodies
01
Overview
Phase 1, open-label trial of porustobart in melanoma and solid tumor (2 arms), sponsored by Harbour BioMed. Primary endpoints: Maximum Tolerated Dose at 42 days, Recommended Phase 2 Dose at 42 days and 2 more. Status: unknown.
02
Drugs
porustobart
03
Conditions
melanomasolid tumor
Beyond the preview
Go deeper on NCT04727164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04727164.